Psychedelic Healthcare Implementation

U.S. private payer with published medical policy and prior-authorization requirements for esketamine (Spravato) in treatment-resistant depression pathways.

Canadian public HTA and reimbursement review body supporting evidence appraisal for access decisions.

U.S.-based health economics research center (Tufts Medical Center) that curates the CEA Registry and supports cost-effectiveness and value-assessment research used in market-access decision-making.

U.S. private payer with published psychiatry coverage-position criteria and prior-authorization form requirements specific to Spravato.

Nationwide federal-employee health benefits payer channel (Blue Cross Blue Shield FEP) with published pharmacy policy criteria for Spravato.

Germany’s highest joint self-governing HTA decision body for coverage and evidence appraisal, including esketamine/Spravato dossiers.

Global HEOR professional society with major U.S. footprint and an evidence dissemination platform that includes psychedelic-adjacent esketamine budget-impact analyses.

U.S. value assessment organization that publishes comparative effectiveness and cost-effectiveness reports used by payers and policymakers, including assessments relevant to esketamine.

Nonprofit organizer and host of the Psychedelic Science conference series, alongside broader educational and policy programming.

Massachusetts Medicaid payer program with published prior-authorization resources and pharmacy updates that include Spravato-related coverage changes.

UK HTA body issuing evidence and cost-effectiveness recommendations that influence medicine access.

Nevada's Medicaid authority publishing pharmacy and physician-administered drug policy materials used for access and prior-authorization decisions, including Spravato-related references in archived DUR and update documents.

State-level Oregon pharmacy and therapeutics decision body supporting evidence-driven formulary and utilization policy.

Australia’s HTA and reimbursement advisory body for PBS listing decisions, including esketamine (Spravato) assessment materials.

Scotland’s public HTA body issuing medicine acceptance guidance, including esketamine (Spravato) advice.

U.S. private payer with national provider-facing prior-authorization criteria for Spravato and medical policy criteria that include ketamine/esketamine use conditions.

U.S. Veterans Health Administration payer and formulary authority publishing criteria-for-use and national protocol documents for intranasal esketamine (Spravato).

Washington State HTA program conducting evidence review that informs state coverage and utilization policy.

Canadian pan-jurisdictional payer negotiation body that coordinates joint drug price negotiations for public plans, including completed negotiations for Spravato (esketamine).